CEDARHURST, N.Y., April 01, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues
the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in
these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff
and a preliminary estimate of their recoverable losses.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a
settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from
investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff
and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is
not required to partake in any recovery.
Uxin Limited (NASDAQGS: UXIN)
Investors Affected: Pursuant and/or traceable to the Company’s Registration Statement and Prospectus issued in connection
with the June 27, 2018 initial public offering
A class action has commenced on behalf of certain shareholders in Uxin Limited. The Registration Statement was materially false
and misleading and omitted to state that: (1) Uxin was likely to stop providing complementary services such as inspections to its
customers; (2) instead, Uxin would connect consumers to dealers who would provide such complementary services; (3) as a result,
Uxin’s 2B business would be materially impacted; and (4) consequently, Defendants’ statements in the Registration Statement
regarding Uxin’s business, operations, and prospects, were materially false and/or misleading.
Shareholders may find more information at https://kclasslaw.com/securities/uxin-limited-loss-submission-form/?wire=3
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
Investors Affected: August 4, 2016 - January 31, 2019
A class action has commenced on behalf of certain shareholders in AVEO Pharmaceuticals, Inc. The filed complaint alleges that
defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately
designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013;
(ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of
sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public
statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/aveo-pharmaceuticals-inc-loss-submission-form/?wire=3
Alta Mesa Resources, Inc. (AMR) f/k/a Silver Run Acquisition Corporation II (NASDAQCM: AMR)
Investors Affected: Purchasers of Silver Run II securities March 24, 2017-February 25, 2019 and investors who held Silver
Run II Class A common stock as of January 22, 2018 and were entitled to vote concerning Silver Run II's acquisition of Alta Mesa
and Kingfisher Midstream LLC
A class action has commenced on behalf of certain shareholders in Alta Mesa Resources, Inc (AMR) f/k/a Silver Run Acquisition
Corporation II. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to
disclose that: (1) Alta Mesa and Kingfisher did not possess “superior quality” and “[w]orld [c]lass” assets as compared to other
operators in the oil and gas industry; (2) Alta Mesa faced significant operational setbacks; (3) several major oil producers had
steered assets away from production in the region in which Alta Mesa operates; and (4) Kingfisher and Alta Mesa were not on track
to achieve the earnings and production estimates provided in the Proxy and Defendants had no reasonable basis to believe and did
not believe that Kingfisher and Alta Mesa would achieve these estimates.
Shareholders may find more information at https://kclasslaw.com/securities/alta-mesa-resources-inc-amr-f-k-a-silver-run-acquisition-corporation-ii-loss-submission-form/?wire=3
United Microelectronics Corporation (NYSE: UMC)
Investors Affected: October 28, 2015 - November 1, 2018
A class action has commenced on behalf of certain shareholders in United Microelectronics Corporation. The filed complaint
alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) UMC conspired with
Fujian to steal trade secrets from Micron relating to its research and development of Dynamic Random-Access Memory ("DRAM"); (ii)
UMC hired former Micron employees for the purpose of stealing such information from Micron; (iii) the foregoing conduct placed UMC
and certain of its employees at an increased risk of criminal and regulatory investigation by the U.S. government; and (iv) as a
result, UMC’s public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/united-microelectronics-corporation-loss-submission-form/?wire=3
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in
good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading
statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.
CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967
